0.10Open0.05Pre Close40 Volume10 Open Interest3.00Strike Price400.00Turnover134.71%IV20.16%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.3732Delta0.4739Gamma14.74Leverage Ratio-0.0080Theta0.0004Rho5.50Eff Leverage0.0022Vega
Corvus Pharmaceuticals Stock Discussion
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024
Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024
Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefin...
NEWS
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
NEWS
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
No comment yet